Gates Package — page 248

Members of the Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) Partnership Lawrence Tabak, D.D.S., Ph.D. Principal Deputy Director NIH Brigadier General Michael Talley Commanding General U.S. Army Medical Research and Development Command John Tsai, M.D. Head of Global Drug Development and Chief Medical Officer Novartis Rupert Vessey, M.A., B.M., B.Ch., F.R.C.P., D.Phil. Executive Vice President, Research and Early Development Bristol Myers Squibb Herbert Virgin, M.D., Ph.D. Executive Vice President, Research; Chief Scientific Officer Vir Biotechnology Janet Woodcock, M.D. Acting Commissioner U.S. Food and Drug Administration John Young, Ph.D. Global Head Infectious Diseases and Vice President Roche ACTIV Preclinical Working Group Peter Adams, Ph.D. Health Scientist, Influenza Division Biomedical Advanced Research and Development Authority Annaliesa Anderson, Ph.D., FAAM Vice President and Chief Scientific Officer, Bacterial Vaccines Pfizer James Anderson, M.D., Ph.D. Director, Division of Program Coordination, Planning, and Strategic Initiatives Office of the Director, NIH Ralph Baric, Ph.D. Professor, Department of Epidemiology and Department of Microbiology and Immunology University of North Carolina, Chapel Hill Kara Carter, Ph.D. Senior Vice President, Discovery Biology